GlobeNewswire

Airline Data Platform ATPCO Acquires Rich Content Provider Routehappy

Dela

The acquisition connects Routehappy's airline rich content with ATPCO's airfare data, transforming the flight shopping experience across all points of sale

DULLES INTERNATIONAL AIRPORT and NEW YORK, Feb. 01, 2018 (GLOBE NEWSWIRE) -- ATPCO, the leading source for airline industry pricing and shopping data, today announced the acquisition of Routehappy, the airline industry's leading rich content provider for flight shopping. The acquisition broadens ATPCO's value to the entire airline distribution ecosystem by enabling rich content, making it a centralized platform for both airfare data and rich content.

"Airline merchandising is rapidly evolving, as rich content is more widely adopted across both NDC and traditional distribution models. As an industry, we want travelers to be able to see, and trust, the differences between flight options," said Jerry Foran, Chairman of the Board of ATPCO and Head of Product Delivery, Revenue Management at British Airways. "This acquisition is another example of how ATPCO is executing on its promise to fuel the future of airline distribution."

Founded in 2011 and based in New York with 19 full-time employees, Routehappy has more than 65 customers across the travel industry including Expedia, Google, Sabre, and United Airlines. Routehappy has paved the way for a more transparent shopping experience for flyers around the world with rich content for over 300 airlines and its APIs delivering over 10 billion queries since its inception. Routehappy's rich content has proven to increase conversion, yield and customer satisfaction for both airlines and distributors. By joining ATPCO, Routehappy's four rich content types-Scores, Amenities, UPAs (Universal Product Attributes) and UTAs (Universal Ticket Attributes)-become an industry standard to rapidly accelerate the adoption of rich content.

"Our acquisition of Routehappy drives strategic innovation, reduces complexity, and delivers network economics to the entire distribution ecosystem. Routehappy has created an offering that solves many of the challenges that airlines encounter in delivering consistent messaging, branding, and merchandising through multiple distribution channels," said ATPCO President and CEO Rolf Purzer. "By aligning Routehappy's complementary rich content with ATPCO's fare and pricing data, airlines can ensure consistent and differentiated offers for their products in every sales channel."

ATPCO works with more than 430 airlines who use its fare and pricing rules content to fuel an estimated 87% of worldwide ticket sales. Bringing together the unmatched rich content offerings of Routehappy with the unparalleled breadth of ATPCO fare data means airlines have greater ease in controlling the look and feel of their offers across all channels of sales. The move further advances ATPCO's vision of empowering smart connection of all content through all channels within the ecosystem. The deal represents ATPCO's first acquisition in its 53-year history, and redoubles its efforts to serve the needs of the next generation of air travel distribution.

"Routehappy has helped United differentiate our products and services in clear and meaningful ways," said Tye Radcliffe, United's Director of Distribution. "The tools Routehappy offers enable a more seamless shopping experience for our travel agents and customers."

According to Robert Albert, Routehappy's founder and CEO, who will continue to lead the company as a strategic business unit of ATPCO, "Routehappy was founded with the mission to differentiate and better monetize flight shopping. ATPCO is a perfect fit for our products and accelerates that mission, allowing Routehappy to become an industry standard for airline rich content for airlines, distributors and technology platforms worldwide. Our solution provides a channel, platform and delivery-agnostic solution. By combining our excellent technology and content with ATPCO's established relationships and scale, we now have a clear path to fulfilling our mission and to help the industry transform."

Routehappy will operate as a wholly owned subsidiary and strategic business unit of ATPCO. The terms of the acquisition are private.

A video announcing the acquisition can be viewed here.

About ATPCO
Uniquely positioned at the center of the airline distribution ecosystem, ATPCO is elevating the future of air travel by providing the advanced technology and valuable industry relationships that shape the way flights are sold. ATPCO manages more than 170 million fares for 430 airlines in 160 countries and supports an average of 3.9 million daily fare changes. Because ATPCO is owned by airlines, they serve as a neutral and trusted partner for airlines, travel agencies, search engines, global distribution systems, and governments worldwide. Every day, these organizations rely on ATPCO's portfolio of technology and data solutions to help millions of travelers get where they need to go. Learn more at atpco.net.

About Routehappy 
Routehappy powers rich content for flight shopping, helping airlines and distributors differentiate and better monetize their products. Routehappy's Scores & Amenities API provides flight scores and cabin amenity data, including aircraft, seat, layout, entertainment, Wi-Fi, power, fresh food and relative duration. Routehappy Hub is a cloud-based offering that helps airlines create, manage and distribute targeted product and ticket attribute content, in standardized formats UPA (Universal Product Attribute) and UTA (Universal Ticket Attribute) wherever flights are displayed. Routehappy is based in New York, serving airlines and distributors worldwide. For more information, visit www.routehappy.com. To see Routehappy rich content in action, visit www.routehappy.com/use-cases.

Tweet This : @ATPCOnews acquires @routehappy, transforming the flight shopping experience everywhere you buy flights

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/2f198429-e3a0-47ff-a7b3-7303300f16a7

Media Contacts
For ATPCO
Michael Mazzocco, +1 703 661 7503, mmazzocco@atpco.net

For Routehappy
Jodi Echakowitz, +1 416 271 7250, jodi@boulevardpr.com
Megan Humphries, +1 917 460 6293, megan@routehappy.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ATPCO via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics appoints a new Chief Medical Officer25.3.2019 11:00:00 CETPressmeddelande

STOCKHOLM, March 25, 2019. Karolinska Development's portfolio company Aprea Therapeutics announces today that Dr. Eyal C. Attar has been appointed to a position as Senior Vice President and Chief Medical Officer (CMO). Dr. Attar joins Aprea from Agios Pharmaceuticals, where he was Senior Medical Director and IDH Hematology Medical Lead. Having served at Agios since 2014, Dr. Attar played a leadership role in the clinical development and approval of Idhifa and Tibsovo for patients with relapsed/refractory Acute Myeloid Leukemia (AML). Prior to Agios, he served on the clinical staff at the Massachusetts General Hospital Cancer Center, where Dr. Attar was a member of the Center for Leukemia and Assistant Professor of Medicine at Harvard Medical School. "Dr. Attar's deep medical and biotech industry experiences will strengthen our clinical development efforts as we continue to advance our first-in-class p53 reactivating agents in late-stage clinical studies", states Christian S. Schade, Pr

Karolinska Development's portfolio company Aprea Therapeutics appoints a new Chief Medical Officer25.3.2019 11:00:00 CETPressmeddelande

STOCKHOLM, March 25, 2019. Karolinska Development's portfolio company Aprea Therapeutics announces today that Dr. Eyal C. Attar has been appointed to a position as Senior Vice President and Chief Medical Officer (CMO). Dr. Attar joins Aprea from Agios Pharmaceuticals, where he was Senior Medical Director and IDH Hematology Medical Lead. Having served at Agios since 2014, Dr. Attar played a leadership role in the clinical development and approval of Idhifa and Tibsovo for patients with relapsed/refractory Acute Myeloid Leukemia (AML). Prior to Agios, he served on the clinical staff at the Massachusetts General Hospital Cancer Center, where Dr. Attar was a member of the Center for Leukemia and Assistant Professor of Medicine at Harvard Medical School. "Dr. Attar's deep medical and biotech industry experiences will strengthen our clinical development efforts as we continue to advance our first-in-class p53 reactivating agents in late-stage clinical studies", states Christian S. Schade, Pr

Immunicum AB (publ) meddelar kommande konferenser i mars och april22.3.2019 08:00:00 CETPressmeddelande

Pressmeddelande 22 mars 2019 Immunicum AB (publ) meddelar kommande konferenser i mars och april Immunicum AB (publ; IMMU.ST) meddelar idag att medlemmar av ledningsgruppen kommer att delta och presentera vid kommande konferenser i mars och april. BIO-Europe Spring Datum: 25-27 mars 2019 Plats: Messe Wien Exhibition and Congress Center, Wien, Österrike Deltagare: Sijme Zeilemaker China Focus @ Europe Vienna Datum: 27 mars 2019 Paneltid/Sessionstid: 16.10 - 17.00, Panel 4: Partnering Opportunities with Chinese Pharma Plats: Hilton Vienna Danube Waterfront, Wien, Österrike Deltagare: Carlos de Sousa Swedish American Life Science Summit 2019 Datum: 9-10 april 2019 Presentationsdatum: Onsdagen 10 april 2019 Plats: House of Sweden, 2900 K St. NW, Washington D.C. 20008 Deltagare: Carlos de Sousa För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 8 732 8400 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@i

Immunicum AB (publ) Announces Upcoming Conferences in March and April22.3.2019 08:00:00 CETPressmeddelande

Press Release 22 March 2019 Immunicum AB (publ) Announces Upcoming Conferences in March and April Immunicum AB (publ; IMMU.ST) announced today that members of the management team will attend and present at upcoming conferences in March and April. BIO-Europe Spring Date: March 25-27, 2019 Venue: Messe Wien Exhibition and Congress Center, Vienna, Austria Participant: Sijme Zeilemaker China Focus @ Europe Vienna Date: March 27, 2019 Panel Time/Session: 16.10 - 17.00, Panel 4: Partnering Opportunities with Chinese Pharma Venue: Hilton Vienna Danube Waterfront, Vienna, Austria Participant: Carlos de Sousa Swedish American Life Science Summit 2019 Date: April 9-10, 2019 Presentation Date: Wednesday, April 10, 2019 Venue: House of Sweden, 2900 K St. NW, Washington D.C. 20008 Participant: Carlos de Sousa For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 8 732 8400 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir

Karolinska Development's portfolio company Promimic announces partnership with Onkos Surgical15.3.2019 08:45:00 CETPressmeddelande

STOCKHOLM, March 15, 2019. Karolinska Development's portfolio company Promimic announces a new partnership with the U.S company Onkos Surgical® to commercialize Promimic's proprietary Hydroxyapatite (HA) Surface Technologies in Limb Salvage Surgery. Promimic develops and markets products within nano-materials for innovative surface treatments and has developed the HA nano Surface that is clinically proven to speed up and improve the anchoring of implants in bone. The innovative technology is already licensed to several dental implant companies. The partnership with Onkos Surgical®, a U.S company addressing the clinical challenges associated with tumor surgery, represents an important step into the orthopaedic space. The partnership will focus on combining Promimic's HA nano Surface Technology with Onkos Surgical®'s ELEOS Limb Salvage Portfolio. Implant failure due to aseptic loosening remains one of the key challenges associated with limb salvage surgery. With HA nano Surface, Onkos Su

Karolinska Development's portfolio company Promimic announces partnership with Onkos Surgical15.3.2019 08:45:00 CETPressmeddelande

STOCKHOLM, March 15, 2019. Karolinska Development's portfolio company Promimic announces a new partnership with the U.S company Onkos Surgical® to commercialize Promimic's proprietary Hydroxyapatite (HA) Surface Technologies in Limb Salvage Surgery. Promimic develops and markets products within nano-materials for innovative surface treatments and has developed the HA nano Surface that is clinically proven to speed up and improve the anchoring of implants in bone. The innovative technology is already licensed to several dental implant companies. The partnership with Onkos Surgical®, a U.S company addressing the clinical challenges associated with tumor surgery, represents an important step into the orthopaedic space. The partnership will focus on combining Promimic's HA nano Surface Technology with Onkos Surgical®'s ELEOS Limb Salvage Portfolio. Implant failure due to aseptic loosening remains one of the key challenges associated with limb salvage surgery. With HA nano Surface, Onkos Su

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum